SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021)


Por: Remon, J, Bernabe, R, Diz, P, Felip, E, Gonzalez-Larriba, JL, Lazaro, M, Mielgo-Rubio, X, Sanchez, A, Sullivan, I, Massutti, B

Publicada: 1 abr 2022 Ahead of Print: 1 feb 2022
Resumen:
Thymic epithelial tumours (TET) represent a heterogeneous group of rare malignancies that include thymomas and thymic carcinoma. Treatment of TET is based on the resectability of the tumour. If this is considered achievable upfront, surgical resection is the cornerstone of treatment. Platinum-based chemotherapy is the standard regimen for advanced TET. Due to the rarity of this disease, treatment decisions should be discussed in specific multidisciplinary tumour boards, and there are few prospective clinical studies with new strategies. However, several pathways involved in TET have been explored as potential targets for new therapies in previously treated patients, such as multi-tyrosine kinase inhibitors with antiangiogenic properties and immune checkpoint inhibitors (ICI). One third of patient with thymoma present an autoimmune disorders, increasing the risk of immune-related adverse events and autoimmune flares under ICIs. In these guidelines, we summarize the current evidence for the therapeutic approach in patients with TET and define levels of evidence for these decisions.

Filiaciones:
Remon, J:
 HM Hosp, Ctr Integral Oncol Clara Campal HM CIOCC, Hosp HM Nou Delfos, Dept Med Oncol, Avinguda Vallcarca 151, Barcelona 08023, Spain

Bernabe, R:
 Hosp Univ Virgen del Rocio, Dept Med Oncol, Seville, Spain

Diz, P:
 Univ Leon, Dept Med Oncol, Leon, Spain

Felip, E:
 Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain

 Vall dHebron Inst Oncol VHIO, Barcelona, Spain

Gonzalez-Larriba, JL:
 Hosp Univ Clin San Carlos, Dept Med Oncol, Madrid, Spain

Lazaro, M:
 Hosp Alvaro Cunqueiro, Dept Med Oncol, Vigo, Spain

Mielgo-Rubio, X:
 Hosp Univ Fdn Alcorcon, Dept Med Oncol, Madrid, Spain

Sanchez, A:
 Consorcio Hosp Prov Castellon, Dept Med Oncol, Castellon de La Plana, Spain

Sullivan, I:
 Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain

Massutti, B:
 Hosp Gen Univ Alicante, Dept Med Oncol, Alicante, Spain
ISSN: 1699048X





Clinical & Translational Oncology
Editorial
SPRINGER INTERNATIONAL PUBLISHING AG, GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND, España
Tipo de documento: Article
Volumen: 24 Número: 4
Páginas: 635-645
WOS Id: 000751591900002
ID de PubMed: 35122634
imagen Green Published, hybrid

MÉTRICAS